Becton, Dickinson and Co.

Becton Dickinson's RSI of 29.7 signals oversold conditions, yet the stock trades at a P/E of 23.48—above the medical device sector median—suggesting the market hasn't fully repriced downside risk. The modest 2.87% short interest provides minimal squeeze catalyst, while the $43.9B cap reflects a mature, established player lacking high-growth narratives. This disconnect between technical weakness and elevated valuation multiples hints at either a genuine opportunity for mean reversion or confirmation that fundamental deterioration justifies premium pricing. The absence of extreme short positioning limits relief rally potential.